Compugen (NASDAQ:CGEN) Shares Cross Above 200-Day Moving Average of $1.57

Compugen Ltd. (NASDAQ:CGEN) shares passed above its two hundred day moving average during trading on Wednesday . The stock has a two hundred day moving average of $1.57 and traded as high as $2.44. Compugen shares last traded at $2.43, with a volume of 145,661 shares.

Analyst Ratings Changes

A number of research firms have weighed in on CGEN. Stifel Nicolaus raised their target price on shares of Compugen from $3.00 to $4.00 and gave the stock a “buy” rating in a research note on Tuesday, December 19th. StockNews.com raised shares of Compugen from a “hold” rating to a “buy” rating in a research note on Wednesday, March 6th.

Compugen Stock Up 3.8 %

The stock has a market capitalization of $210.49 million, a PE ratio of -11.05 and a beta of 2.63. The business’s 50-day moving average is $2.49 and its two-hundred day moving average is $1.57.

Compugen (NASDAQ:CGEN) last announced its earnings results on Tuesday, March 5th. The biotechnology company reported $0.11 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.10 by $0.01. The firm had revenue of $33.46 million for the quarter, compared to analyst estimates of $60.00 million. As a group, analysts anticipate that Compugen Ltd. will post 0.02 EPS for the current year.

Institutional Trading of Compugen

A number of hedge funds have recently bought and sold shares of CGEN. Sphera Funds Management LTD. acquired a new stake in Compugen during the second quarter worth approximately $1,402,000. Two Sigma Advisers LP boosted its position in Compugen by 855.7% during the third quarter. Two Sigma Advisers LP now owns 1,344,584 shares of the biotechnology company’s stock worth $883,000 after acquiring an additional 1,203,900 shares during the last quarter. Renaissance Technologies LLC boosted its holdings in shares of Compugen by 82.5% in the 3rd quarter. Renaissance Technologies LLC now owns 2,372,648 shares of the biotechnology company’s stock valued at $1,559,000 after purchasing an additional 1,072,576 shares during the last quarter. Two Sigma Investments LP boosted its holdings in shares of Compugen by 200.4% in the 3rd quarter. Two Sigma Investments LP now owns 1,518,059 shares of the biotechnology company’s stock valued at $997,000 after purchasing an additional 1,012,763 shares during the last quarter. Finally, Silverarc Capital Management LLC acquired a new position in shares of Compugen in the 4th quarter valued at $478,000. Institutional investors and hedge funds own 12.22% of the company’s stock.

Compugen Company Profile

Compugen Ltd., a clinical-stage therapeutic discovery and development company, researches, develops, and commercializes therapeutic and product candidates in Israel, the United States, and Europe. The company's immuno-oncology pipeline consists of COM701, an anti-PVRIG antibody that is in Phase I clinical study used for the treatment of solid tumors; COM902, a therapeutic antibody targeting TIGIT, which is in Phase I monotherapy clinical study in patients with advanced malignancies through sequential dose escalations; Bapotulimab, a therapeutic antibody targeting ILDR2 that is in Phase I clinical study in patients with naïve head and neck squamous cell carcinoma; and Rilvegostomig, a novel anti-TIGIT/PD-1 bispecific antibody, which is in Phase II clinical study in patients with advanced or metastatic non-small cell lung cancer.